Ubrelvy access in the UAE: the EDE named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team. This page describes the named-patient pathway for Ubrelvy in the UAE for adult patients with episodic migraine where local oral options are not appropriate or have failed.

Section 1. Quick orientation

Ubrelvy is the brand name for ubrogepant, an oral small-molecule calcitonin gene-related peptide receptor antagonist in the gepant class, FDA-approved in December 2019 for the acute treatment of migraine with or without aura in adults. It is not registered with the Emirates Drug Establishment (EDE) or with the Ministry of Health and Prevention (MOHAP) for commercial sale in the UAE. For adult patients in the UAE whose treating neurologist has selected ubrogepant as the right next step, typically because triptans have failed, are contraindicated, or are not tolerated, the lawful access route is the unregistered-medicine personal-use import permit administered by the EDE. Reserve Meds coordinates the US-side sourcing, documentation kit, and international logistics under a single named coordinator. The clinical decision remains with your physician. Reserved for you.

Section 2. Why UAE patients need Ubrelvy through a named-patient pathway

The UAE operates one of the most developed pharmaceutical regulatory environments in the Gulf Cooperation Council. The Emirates Drug Establishment, which assumed 44 core regulatory services from MOHAP on 29 December 2025 under Federal Decree-Law No. 38 of 2024, maintains the national drug register, issues marketing authorisations, and runs the unregistered-medicine personal-use import permit pathway. Three structural access gaps recur across UAE patient cases: drugs registered but not stocked at a particular hospital, drugs registered for a different indication than the one the physician is treating, and drugs not registered in the UAE at all. Ubrelvy sits firmly in the third category.

AbbVie, which acquired the original developer Allergan in May 2020, has not pursued EDE marketing authorisation for ubrogepant. The drug is not stocked through Dubai, Abu Dhabi, Sharjah, or Northern Emirates retail or hospital pharmacy networks, and it does not appear on the EDE register. Patients reading about gepants in international migraine literature, patients whose neurologists at major UAE academic centres have specifically recommended an oral CGRP receptor antagonist, and patients returning to the UAE from US treatment with an established response to Ubrelvy all encounter the same reality: no local commercial source exists. The registration gap is durable. AbbVie has not indicated EDE filing on its near-term portfolio plan, and the unregistered-medicine pathway is therefore the only lawful route to authentic US-supplied Ubrelvy in the UAE.

Section 3. The EDE named-patient pathway for Ubrelvy

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered locally is the unregistered-medicine import permit, historically administered by MOHAP and, from 29 December 2025, administered through the EDE portal at ede.gov.ae. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority, in this case the US FDA, and a clinically equivalent locally registered alternative is not suitable. The UAE legal framework's compassionate-use provisions describe the use of a medical product for a patient with a serious illness or condition outside of clinical trials when no alternative treatment options are available; migraine that has failed triptans or that carries triptan contraindications fits that frame.

A complete application for Ubrelvy typically includes a clinical justification letter from the treating physician documenting migraine diagnosis, frequency and severity, prior abortive therapies tried and their outcomes (sumatriptan, rizatriptan, eletriptan, over-the-counter analgesics), the clinical reason a triptan is not suitable (cardiovascular contraindication, intolerance, refractoriness), and the rationale for selecting ubrogepant specifically over Nurtec ODT (rimegepant) or other oral options. The treating physician's UAE medical license is verified through the issuing authority (MOHAP for Northern Emirates, Dubai Health Authority for Dubai, Department of Health Abu Dhabi for Abu Dhabi, or Sharjah Health Authority for Sharjah). The application also names the dispensing facility, the pharmacy in charge, the requested pack size, the intended treatment duration, and the chain-of-custody plan from the US wholesaler through the importer to the dispensing pharmacy.

The cell-specific clinical-justification angle for Ubrelvy is the documentation of prior-line failure or triptan unsuitability. Unlike rare oncology cases where the clinical justification rests on a confirmatory biomarker, an Ubrelvy file rests on a documented migraine history: the diagnosis (ICD-10 G43 series), monthly migraine day count, prior abortives and their failure mode (lack of response, intolerable side effects, or cardiovascular contraindication to triptans), and the prescriber's stated reason for selecting ubrogepant over Nurtec ODT. The 8-dose-per-30-day FDA-labeled ceiling is referenced in the letter and aligns the requested pack size to a clinically reasonable monthly exposure. Approval timelines for routine cases are typically 5 to 15 business days. First imports of a given molecule or unusually large quantities can extend to 4 to 6 weeks at the authority's discretion.

Section 4. Where Ubrelvy gets dispensed in the UAE

A small group of UAE institutions handle named-patient imports as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. For Ubrelvy, the relevant capability is neurology and a hospital outpatient pharmacy able to dispense an oral medicine; the room-temperature handling profile means no specialised cold-chain pharmacy infrastructure is required. Cleveland Clinic Abu Dhabi (M42 group, Al Maryah Island) and Sheikh Khalifa Medical City (SEHA network, Abu Dhabi) carry strong neurology service lines and routinely file unregistered-medicine permits. American Hospital Dubai (Mayo Clinic Care Network member), King's College Hospital London Dubai, and Mediclinic City Hospital in Dubai Healthcare City similarly hold pharmaceutical establishment licenses and dispense imported neurology medicines. NMC Healthcare's flagship Dubai and Abu Dhabi sites also handle these cases.

For patients whose treating neurologist practices at a smaller hospital or a clinic without internal import infrastructure, the common pattern is to route through a Dubai- or Abu Dhabi-based specialty importer that holds a pharmaceutical establishment license and files the EDE application on the prescribing physician's behalf. The importer performs customs clearance, takes receipt of the shipment under chain-of-custody documentation, and delivers the medicine to the prescribing hospital's outpatient pharmacy. The treating physician's clinical justification letter remains the cornerstone of the file regardless of who files it. Patients resident in the Northern Emirates without a local specialty hospital typically route to a Dubai or Abu Dhabi centre where their treating physician holds joint privileges or where the case is co-managed with a UAE-licensed neurologist.

Section 5. Real cost picture for Ubrelvy in the UAE

The UAE dirham is pegged to the US dollar at approximately 3.67 AED to 1 USD, so cost ranges quoted in USD translate predictably into AED. Reserve Meds quotes are itemised, not bundled.

• Drug cost reference. US wholesale acquisition cost for Ubrelvy is approximately USD 1,140 per 10-tablet pack of 50 mg or 100 mg as of January 2026, equivalent to roughly USD 114 per tablet at WAC. GoodRx and SingleCare retail cash reference prices in early 2026 ranged from approximately USD 1,086 to USD 1,464 per 10-tablet 100 mg pack. International cash-pay procurement for named-patient orders prices above US retail in line with NPP norms for branded specialty migraine therapy.
• International logistics. Ambient room-temperature shipping for an oral small molecule, USD 400 to 1,500 (approximately AED 1,500 to 5,500) depending on destination emirate and urgency window. No cold chain is required for ubrogepant, which keeps the logistics layer at the lower end of the matrix.
• Regulatory and concierge. EDE permit fees and customs handling are nominal relative to the drug cost. Reserve Meds' concierge coordination fee is itemised separately on every firm quote.

UAE health insurance is mandatory. Daman National Health Insurance (operator of the government-funded Thiqa programme for UAE nationals), GIG Gulf (formerly AXA Gulf), Sukoon Insurance (formerly Oman Insurance Company), ADNIC, and Orient Insurance each handle named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage, and many require pre-authorisation. Reserve Meds supplies the documentation set that lets an insurer assess; the claim sits with you or your hospital. Cash-pay is the default posture.

Section 6. Typical timeline for Ubrelvy in the UAE

The room-temperature handling profile makes Ubrelvy one of the lower-friction logistics cases in the Reserve Meds matrix. There is no cold-chain validation window, no temperature-loggers to reconcile at handoff, and no in-transit reconstitution risk. The end-to-end timeline therefore tracks the regulatory layer rather than the supply chain. EDE permit issuance for routine cases is typically 5 to 15 business days from filing. US-side procurement through the open AbbVie wholesaler chain (McKesson, Cardinal Health, Cencora) runs in parallel during the permit window. Once the permit is issued, ambient air freight under standard pharmaceutical-grade packaging clears UAE customs within 2 to 5 business days. Hospital pharmacy receipt, verification, and release to the treating physician completes the cycle. A reasonable end-to-end estimate from intake to first dose in hand is 3 to 5 weeks for a first import; refill cycles for a patient already established on the drug compress to 2 to 3 weeks because the documentation reuses the original prescriber file. These ranges are typical, not promises.

Section 7. What your physician needs to provide

The clinical justification letter is the cornerstone of the EDE application. For Ubrelvy, the letter should contain the patient identifier (anonymised reference where the EDE submission allows), the migraine diagnosis with ICD-10 coding, a documented monthly migraine day frequency and severity (typically MIDAS or HIT-6 score where available), a prior-therapy history naming the specific triptans and other abortives tried with their outcomes (lack of response, intolerable adverse effects such as chest tightness or paresthesias, or a clinical contraindication such as coronary artery disease, uncontrolled hypertension, prior ischemic stroke or TIA, or peripheral vascular disease), and the rationale for selecting ubrogepant specifically. Where the prescriber considered Nurtec ODT (rimegepant) or another gepant and selected ubrogepant, a one-sentence reason in the letter accelerates EDE review.

Dosing in the letter aligns with the FDA-approved label: 50 mg or 100 mg orally at the onset of a migraine attack, with a second dose permitted at least 2 hours after the first if needed, a maximum of 200 mg in 24 hours, and a labeled ceiling of 8 doses per 30-day period. The letter should reference the prescriber's intended monthly exposure (one pack of 10 tablets typically covers a month for a patient with up to 8 migraine days). Concomitant-medication review for strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, ritonavir-boosted regimens), where dose adjustment is required or co-administration is contraindicated, should be documented. Renal and hepatic function status is noted for patients where dose reduction applies. The treating physician's UAE medical license number, issuing authority (MOHAP, DHA, DOH, or Sharjah Health Authority), and the dispensing facility's pharmaceutical establishment license complete the package.

Section 8. Common questions about Ubrelvy in the UAE

Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover this? Each insurer assesses named-patient imports case by case. Thiqa, administered by Daman for UAE nationals, has the broadest specialty coverage in Abu Dhabi. We do not promise coverage from any insurer. We supply the documentation that allows your insurer to assess; the claim itself sits with you or your hospital.

Will my DHA-licensed or DOH-licensed physician's letter be sufficient? Yes. Any UAE-licensed physician practicing in good standing in the emirate of the dispensing facility has signing authority on the clinical justification letter. The letter must match the emirate of the dispensing facility (DHA for Dubai, DOH for Abu Dhabi, MOHAP for Northern Emirates, SHA for Sharjah).

Can I receive Ubrelvy at home? The dispensing facility must be UAE-licensed. For an oral medicine like Ubrelvy, a hospital outpatient pharmacy or a specialised import pharmacy dispenses the supply. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.

What is the safety profile? The most common adverse events in the ACHIEVE I and ACHIEVE II pivotal trials were nausea, somnolence, and dry mouth, each in single-digit percentages of patients. There were no serious treatment-related adverse events and no discontinuations for adverse events in the pivotal trials. Ubrogepant does not produce the vasoconstriction associated with triptans, which is the defining cardiovascular safety advantage of the gepant class.

How is Ubrelvy different from Nurtec ODT? Both are oral gepants. Ubrelvy is FDA-approved for acute treatment only. Nurtec ODT carries a dual acute-plus-preventive indication on a single molecule. For a patient who needs only acute treatment, both are reasonable; for a patient who needs prevention alongside acute, the dual-indication Nurtec label may be more attractive. The selection is clinical and stays with your prescriber.

Does Ubrelvy interact with anti-CGRP injectable preventives? Co-administration with CGRP monoclonal antibodies used for prevention (erenumab, galcanezumab, fremanezumab, eptinezumab) is common practice and not contraindicated. Reserve Meds does not endorse specific regimens. The prescribing clinician makes the call.

Section 9. Where Reserve Meds fits in Ubrelvy cases

Reserve Meds is a US-based concierge coordinator. We do not replace your physician, do not replace the Emirates Drug Establishment, and do not replace your dispensing pharmacy. For Ubrelvy specifically, the orchestration we provide is a documentation kit your physician uses to assemble the EDE application, US-side procurement through the open AbbVie wholesaler chain, ambient air-freight logistics under pharmaceutical-grade packaging, customs documentation aligned to the permit, and a single named coordinator who stays with your case from intake through delivery. The room-temperature handling profile of ubrogepant makes the logistics layer simpler than for cold-chain biologics; the case management still requires the same documentation rigour. No prior Reserve Meds case experience exists for Ubrelvy at the date of this page. Standard NPP coordination applies.

Section 10. Next step

If your neurologist has selected Ubrelvy for your migraine and you are based in the UAE, the next step is the waitlist. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician. Reserved for you.

---

This guide is informational, not medical or legal advice. The named-patient framework requires a licensed UAE physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.